inclusion criteria: * if on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination * participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at screening. participant may have underlying illnesses, as long as the symptoms and signs are medically controlled * participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere) * participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine * participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study * participant either received their last covid-19 vaccination with an authorized/licensed covid-19 vaccine (at least 4 months prior to first study vaccination) or is covid 19 vaccine-naïve

inclusion criteria: * if on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination * participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at screening. participant may have underlying illnesses, as long as the symptoms and signs are medically controlled * participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere) * participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine * participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study * participant either received their last covid-19 vaccination with an authorized/licensed covid-19 vaccine (at least 4 months prior to first study vaccination) or is covid 19 vaccine-naïve

inclusion criteria: if on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at screening. participant may have underlying illnesses, as long as the symptoms and signs are medically controlled participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere) participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study participant either received their last covid-19 vaccination with an authorized/licensed covid-19 vaccine (at least 4 months prior to first study vaccination) or is covid 19 vaccine-naïve

inclusion criteria: if on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at screening. participant may have underlying illnesses, as long as the symptoms and signs are medically controlled participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere) participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study participant either received their last covid-19 vaccination with an authorized/licensed covid-19 vaccine (at least 4 months prior to first study vaccination) or is covid 19 vaccine-naïve

None

None

inclusion criteria: if on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at screening. participant may have underlying illnesses, as long as the symptoms and signs are medically controlled participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere) participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study participant either received their last covid-19 vaccination with an authorized/licensed covid-19 vaccine (at least 4 months prior to first study vaccination) or is covid 19 vaccine-naïve

inclusion criteria: if on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at screening. participant may have underlying illnesses, as long as the symptoms and signs are medically controlled participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere) participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study participant either received their last covid-19 vaccination with an authorized/licensed covid-19 vaccine (at least 4 months prior to first study vaccination) or is covid 19 vaccine-naïve

inclusion criteria: if on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at screening. participant may have underlying illnesses, as long as the symptoms and signs are medically controlled participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere) participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study participant either received complete primary vaccination with an authorized/licensed covid-19 vaccine (completed at least 6 months prior to first study vaccination) or is covid 19 vaccine-naïve

inclusion criteria: if on medication for a condition, the medication dose must have been stable for at least 4 weeks preceding vaccination participant must be healthy as confirmed by medical history, physical examination, vital signs, and obstetric history performed at screening. participant may have underlying illnesses, as long as the symptoms and signs are medically controlled participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (or not longer than 10 days prior to vaccination if performed elsewhere) participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study participant either received complete primary vaccination with an authorized/licensed covid-19 vaccine (completed at least 6 months prior to first study vaccination) or is covid 19 vaccine-naïve

inclusion criteria: if on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study participant will be included on the basis of physical examination, medical history, and vital signs participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (unless performed elsewhere within 28-days prior to vaccination) participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study

inclusion criteria: if on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study participant will be included on the basis of physical examination, medical history, and vital signs participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation (inclusive), at the time of vaccination, based on ultrasound at the time of screening (unless performed elsewhere within 28-days prior to vaccination) participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study

inclusion criteria: - if on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study - participant will be included on the basis of physical examination, medical history, and vital signs - participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation(inclusive), at the time of vaccination, based on ultrasound at the time of screening (unless performed elsewhere within 28-days prior to vaccination) - participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine - participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study

inclusion criteria: - if on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study - participant will be included on the basis of physical examination, medical history, and vital signs - participant will be at second or third trimester of pregnancy, that is, week 16 to week 38 of gestation(inclusive), at the time of vaccination, based on ultrasound at the time of screening (unless performed elsewhere within 28-days prior to vaccination) - participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine - participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study

inclusion criteria: - if on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study - participant will be included on the basis of physical examination, medical history, and vital signs - participant will be at second or third trimester of pregnancy, that is, week 20 to week 36 of gestation, at the time of randomization, based on ultrasound at the time of screening (unless performed elsewhere within 28-days prior to vaccination) - participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine - participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study

inclusion criteria: - if on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study - participant will be included on the basis of physical examination, medical history, and vital signs - participant will be at second or third trimester of pregnancy, that is, week 20 to week 36 of gestation, at the time of randomization, based on ultrasound at the time of screening (unless performed elsewhere within 28-days prior to vaccination) - participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine - participant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study